In which a First-in-Human study in non-Hodgkin&39.

We are very very happy to give priority to our fully owned portfolio and to realise value from our stake in the ADC-1013 project. We are also pleased that people have been in a position to donate to the joint project with Alligator Bioscience , says BioInvent's CEO Michael Oredsson.. Alligator Bioscience acquires rights to drug development candidate ADC-1013 BioInvent International Stomach today announced that the company has sold back again all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum. BioInvent will continue steadily to focus its initiatives on its fully owned drug development candidates BI-505 in stage II for Multiple Myeloma and BI-1206, in which a First-in-Human study in non-Hodgkin's Lymphoma is expected to start late 2014/early 2015.The American Diabetes Association lately added the A1C laboratory test to its list of assessments recommended for identifying diabetes. Related StoriesStudy explores diabetes screening for individuals with serious mental illnessWeight-loss surgery could be secure for managing type 2 diabetes in individuals with mild obesityStudy finds high prevalence of dehydration in older people living in UK treatment homesThe fact you do not have to fast before getting the test makes it a lot more convenient and customer friendly, Mertz says.